
Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IPCALAB | BSE
11.45
1.02%
Healthcare
Drug Manufacturers-Specialty & Generic
30/09/2023
30/11/2023
1,132.75
1,121.35
1,135.00
1,116.85
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive anti-malarial diuretic DMARD and anthelmintic. The company provides generic and branded formulations in the therapeutic segments including allergy anti-neoplastic/cancer drugs anti-arthritic anti-epileptic anti-hypertensive cardiology dermatology diabetology gastroenterology haematology neurology ophthalmology rheumatology and urology as well as respiratory psychiatry probiotics orthopedics oral anti diabetes drug nutraceuticals NSAIDs neuropathic pain malaria infectious diseases immunosuppressant hepatoprotectives helminthics fever and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai India.
View LessPositive Momentum
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Midcap (2B - 10B USD)
Weak P/E, and PEG ratio indicator
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
23.0%1 month
23.7%3 months
24.8%6 months
23.3%56.19
0
3.80
0.32
0.17
18.55
3.63
0
10.45B
287.41B
3.45B
0.18
11.35
0.90
27.00
7.28
0
0
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
85.45
Range1M
168.95
Range3M
277.95
Rel. volume
0.97
Price X volume
19.66M